Takeda, Insilico sign AI drug discovery pact worth up to $600M
Seeking Alpha ·
Hong Kong-listed Insilico Medicine on Thursday announced a partnership with Japanese drugmaker Takeda ( TAK ) to discover, develop, and commercialize drug candidates using artificial intelligence as part of a deal worth up to $600M. Under the collaboration, Boston, Massachusetts-based Insilico will leverage its
DYAX Investor Sentiment
Bullish (Long) 47% · Bearish (Short) 53%
314 participants
Related News
- Service Properties Trust 5-for-1 reverse split takes effect July 6; shares to shrink by 80%
- RH shares gain on insider share purchase
- Tesla hiring Intel vet to help with Terafab seen as 'positive catalyst' for chip giant: Wedbush
- Kratos wins $36M sole-source air defense contract
- Nonfarm payrolls growth cools more than expected in June
- Roche lung cancer therapy beats rivals from Amgen, BMS in late-stage trial